VERTEX PHARMACEUTICALS INC
VRTXNASDAQ🏆 #109 by market capEarnings Nov 2Biotech
$533.41▼ $10.45 (−1.96%)
Simulated price1h—
24h▼ 2.0%
7d▲ 10.0%
14d▲ 10.3%
30d▲ 11.1%
1y▲ 37.5%
🏦Market Cap
$121.09B
Mid Cap
📈Revenue Growth (YoY)
+10.2%
Healthy
📊Gross Margin
86.0%
High
💵FCF Margin
29.5%
Strong
⚖️P/S Ratio
10.1x
Elevated
Otter Score
52
Weak
Trading Snapshot
- Day Range
- $527.90 – $536.18
- 52-Week Range
- $362.50 – $546.17
- Volume
- $4.08B
- Avg Volume
- $5.42B
- Shares Outstanding
- 253.8M
- Next Earnings
- Sep 10, 2026
Fundamentals Snapshot
- Annual Revenue
- $11.94B
- Last Q Revenue
- $3.22B
- P/E Ratio
- 29.0
- P/S Ratio
- 10.1x
- EPS (TTM)
- $17.19
- Dividend Yield
- —
Why Investors Own VRTX
- ✓High-growth profile — revenue up +23.3% YoY with expanding Biotech exposure.
- ✓Healthy economics — 34% gross margin and 9% free-cash-flow margin.
- ✓Deep pipeline with potential catalysts and durable IP.
⚠️ Key Risks
Execution delays, intensifying competition, and valuation compression if growth decelerates.
Financial Trends
Revenue (TTM)
$11.94B▲ +28.8% YoY
Gross Margin (TTM)
33.6%▲ +0.7% YoY
Operating Income (TTM)
$2.89B▲ +28.8% YoY
Free Cash Flow (TTM)
$1.04B▲ +28.8% YoY
About VERTEX PHARMACEUTICALS INC
A company profile for VERTEX PHARMACEUTICALS INC isn’t available yet — check back soon.
🦦
Otter Score Breakdown
ⓘ💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
⚡Momentum★★★★★
Overall Score
Weak
52/100
Analyst Price Target
ⓘAverage Target
$658.55
▲ +23.5% Upside
High Target$764.09
Low Target$575.92
Based on 40 analysts
Latest News & Updates
🚀
MarketWatch·2h ago
VERTEX PHARMACEUTICALS INC tops quarterly estimates as demand accelerates
Revenue grew double digits with management guiding above consensus; margins continued to expand.
🛰️
MarketWatch·5h ago
Analysts lift VRTX price targets on improving margins
Several firms raised targets, citing stronger free cash flow and a healthier backlog.
🌌
Reuters·1d ago
VERTEX PHARMACEUTICALS INC announces new agreement to expand its footprint
The move broadens the company’s reach and could add incremental revenue over the next year.